Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade

References

• André T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, et al. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–7. doi:10.1056/NEJMoa2017699.
   PubMed Web of Science ®Google Scholar
• Lenz HJ, Van Cutsem E, Limon ML, Wong KYM, Hendlisz A, Aglietta M, García-Alfonso P, Neyns B, Luppi G, Cardin DB, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 study. J Clin Oncol. 2022;40(2):161–170. doi:10.1200/JCO.21.01015.
   PubMed Web of Science ®Google Scholar
• Bourdais R, Rousseau B, Pujals A, Boussion H, Joly C, Guillemin A, Baumgaertner I, Nuezillet C, Tournigand C. Polymerase proofreading domain mutations: new opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency. Crit Rev Oncol Hematol. 2017;113:242–248. doi:10.1016/j.critrevonc.2017.03.027.
   PubMed Web of Science ®Google Scholar
• Rousseau B, Foote MB, Maron SB, Diplas BH, Lu S, Argilés G, Cercek A, Diaz LA Jr. The spectrum of benefit from checkpoint blockade in hypermutated tumors. N Engl J Med. 2021;384(12):1168–1170. doi:10.1056/NEJMc2031965.
   PubMed Web of Science ®Google Scholar
• Guven DC, Kavgaci G, Erul E, Syed MP, Magge T, Saeed A, Yalcin S, Sahin IH. The efficacy of immune checkpoint inhibitors in microsatellite stable colorectal cancer: a systematic review. The Oncologist. 2024;29(5):e580–e600. doi:10.1093/oncolo/oyae013.
   PubMedGoogle Scholar
• Wang C, Sandhu J, Ouyang C, Ye J, Lee PP, Fakih M. Clinical response to immunotherapy targeting programmed cell death receptor 1/Programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases. Vol. 4. JAMA Netw Open; 2021. p. e2118416. doi:10.1001/jamanetworkopen.2021.18416.
   Google Scholar
• Yu J, Green MD, Li S, Sun Y, Journey SN, Choi JE, Rizvi SM, Qin A, Waninger JJ, Lang X, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021;27(1):152–164. doi:10.1038/s41591-020-1131-x.
   PubMed Web of Science ®Google Scholar
• Ho WW, Gomes-Santos IL, Aoki S, Datta M, Kawaguchi K, Talele NP, Roberge S, Ren J, Liu H, Chen IX, et al. Dendritic cell paucity in mismatch repair–proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy. Proc Natl Acad Sci USA. 2021;118(45):e2105323118. doi:10.1073/pnas.2105323118.
   PubMed Web of Science ®Google Scholar
• Aasebø KØ, Dragomir A, Sundström M, Mezheyeuski A, Edqvist PH, Eide GE, Ponten F, Pfeiffer P, Glimelius B, Sorbye H. Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: a population-based cohort of metastatic colorectal cancer patients. Cancer Med. 2019;8(7):3623–3635. doi:10.1002/cam4.2205.
   PubMed Web of Science ®Google Scholar
• Cohen R, Liu H, Fiskum J, Adams R, Chibaudel B, Maughan TS, Van Cutsem E, Venook A, Douillard JY, Heinemann V, et al. BRAFV600E mutation in first-line metastatic colorectal cancer: an analysis of individual patient data from the ARCAD database. J Natl Cancer Inst. 2021;113(10):1386–1395. doi:10.1093/jnci/djab042.
   PubMedGoogle Scholar
• Cremolini C, Antoniotti C, Stein A, Bendell J, Gruenberger T, Rossini D, Masi G, Ongaro E, Hurwitz H, Falcone A, et al. Individual patient data meta-analysis of FOLFOXIRI plus bevacizumab versus doublets plus bevacizumab as initial therapy of unresectable metastatic colorectal cancer. J Clin Oncol. 2020;38:3314–3324.
   Web of Science ®Google Scholar
• Van Cutsem E, Taieb J, Yaeger R, Yoshino T, Grothey A, Maiello E, Elez E, Dekervel J, Ross P, Ruiz-Casado A, et al. ANCHOR CRC: results from a single-arm, phase II study of exchorafenib plus binimetinib and cetuximab in previously untreated BRAFV600E-mutant metastatic colorectal cancer. J Clin Oncol. 2023;41:2628–2637.
   PubMed Web of Science ®Google Scholar
• Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer. N Engl J Med. 2019;381(17):1632–1643. doi:10.1056/NEJMoa1908075.
   PubMed Web of Science ®Google Scholar
• Ree AH, Šaltytė Benth J, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Johansen C, Negård A, Bjørnetrø T, et al. First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer—the randomised METIMMOX trial. Br J Cancer. [2024 Apr 25]. 130(12):1921–1928. doi:10.1038/s41416-024-02696-6.
   PubMed Web of Science ®Google Scholar
• Høye E, Dagenborg VJ, Torgunrud A, Lund-Andersen C, Fretland ÅA, Lorenz S, Edwin B, Hovig E, Fromm B, Inderberg EM, et al. T cell receptor repertoire sequencing reveals chemotherapy-driven clonal expansion in colorectal liver metastases. Gigascience. 2022;12:giad032. doi:10.1093/gigascience/giad032.
   PubMed Web of Science ®Google Scholar
• Hill MO. Diversity and evenness: a unifying notation and its consequences. Ecology. 1973;54(2):427–432. doi:10.2307/1934352.
   Web of Science ®Google Scholar
• Ros J, Rodríguez-Castells M, Saoudi N, Baraibar I, Salva F, Tabernero J, Élez E. Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers. Expert Rev Anticancer Ther. 2023;23(8):797–806. doi:10.1080/14737140.2023.2236794.
   PubMed Web of Science ®Google Scholar
• Fakih M, Wang C, Sandhu J, Ye J, Egelston C, Li X. Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases. Eur J Cancer. 2024;196:113437. doi:10.1016/j.ejca.2023.113437.
   PubMed Web of Science ®Google Scholar
• Piringer G, Decker J, Trommet V, Kühr T, Heibl S, Dörfler K, Thaler J. Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: a case report and literature review. Front Oncol. 2023;13:1166545. doi:10.3389/fonc.2023.1166545.
   PubMed Web of Science ®Google Scholar
• Vegivinti CTR, Gomez CG, Syed M, Ferrell M, Cheng S, Singhi A, Saeed A, Sahin IH. The role of immune checkpoint inhibitors for patients with advanced stage microsatellite stable colorectal cancer and high tumor mutation burden: quantity or quality? Expert Opin Biol Ther. 2023;23(7):595–601. doi:10.1080/14712598.2023.2226327.
   PubMed Web of Science ®Google Scholar
• Greiff V, Bhat P, Cook SC, Menzel U, Kang W, Reddy ST. A bioinformatic framework for immune repertoire diversity profiling enables detection of immunological status. Genome Med. 2015;7(1):49. doi:10.1186/s13073-015-0169-8.
   PubMedGoogle Scholar
• Ye J, Guo W, Wang C, Egelston CA, D’Apuzzo M, Shankar G, Fakih MG, Lee PP. Peritumoral immune-suppressive mechanisms impede intratumoral lymphocyte infiltration into colorectal cancer liver versus lung metastases. Cancer Res Commun. 2023;3(10):2082–2095. doi:10.1158/2767-9764.CRC-23-0212.
   PubMedGoogle Scholar
• Dagenborg VJ, Marshall SE, Yaqub S, Grzyb K, Boye K, Lund-Iversen M, Høye E, Berstad AE, Fretland ÅA, Edwin B, et al. Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases. Cancer Biol Ther. 2020;21(5):432–440. doi:10.1080/15384047.2020.1721252.
   PubMed Web of Science ®Google Scholar
• Urbini M, Marisi G, Azzali I, Bartolini G, Chiadini E, Capelli L, Tedaldi G, Angeli D, Canale M, Molinari C, et al. Dynamic monitoring of circulating tumor DNA in patients with metastatic colorectal cancer. JCO Precis Oncol. 2023;7(7):e2200694. doi:10.1200/PO.22.00694.
   PubMedGoogle Scholar
• Roazzi L, Patelli G, Bencardino KB, Amatu A, Bonazzina E, Tosi F, Amoruso B, Bombelli A, Mariano S, Stabile S, et al. Ongoing clinical trials and future research scenarios of circulating tumor DNA for the treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2024;Feb16:S1533–0028(24)00006–9. doi:10.1016/j.clcc.2024.02.001.
   Google Scholar
• Ros J, Matito J, Villacampa G, Comas R, Garcia A, Martini G, Baraibar I, Saoudi N, Salvà F, Martin Á, et al. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ann Oncol. 2023;34(6):543–552. doi:10.1016/j.annonc.2023.02.016.
   PubMed Web of Science ®Google Scholar
• Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–1356. doi:10.1038/nm.3967.
   PubMed Web of Science ®Google Scholar
• Kopetz S, Murphy DA, Pu J, Ciardiello F, Desai J, Grothey A, Van Cutsen E, Wasan HS, Yaeger R, Yoshino T, et al. Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study. J Clin Oncol. 2021;39(15_suppl):3513. doi:10.1200/JCO.2021.39.15_suppl.3513.
   Google Scholar
• van der Pol Y, Yilma B, Morris VK, Chao C, Harris M, Guinney J, Kopetz S. Molecular characterization of microsatellite stable (MSS) colorectal cancer (CRC) patients with a BRAF V600E mutation. Cancer Res. 2024;84(6_Supplement):5056. doi:10.1158/1538-7445.AM2024-5056.
   Google Scholar
• Edin S, Gylling B, Li X, Stenberg Å, Löfgren-Burström A, Zingmark C, van Guelpen B, Ljuslinder I, Ling A, Palmqvist R. Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal cancer – possible implications for immunotherapy. Br J Cancer. 2024;130(1):143–150. doi:10.1038/s41416-023-02483-9.
   PubMed Web of Science ®Google Scholar
• Morris VK, Parseghian CM, Escano M, Johnson B, Raghav KPS, Dasari A, Huey R, Overman MJ, Willis J, Lee MS. et al. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer. J Clin Oncol. 2022;40(suppl):12. doi:10.1200/JCO.2022.40.4_suppl.012.
   PubMedGoogle Scholar